URGN - UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
2024-05-13 18:30:56 ET
UroGen Pharma Ltd. (URGN)
Q1 2024 Earnings Conference Call
May 13, 2024 10:00 AM ET
Company Participants
Vincent Perrone - Head of IR
Elizabeth Barrett - President & CEO
Mark Schoenberg - Chief Medical Officer
Don Kim - CFO
Jeff Bova - Chief Commercial Officer
Conference Call Participants
Tara Bancroft - TD Cowen
Raghuram Selvaraju - H.C. Wainwright & Co
Matt Kaplan - Ladenburg Thalmann
Leland Gershell - Oppenheimer
Presentation
Operator
Good morning ladies and gentlemen. Thank you for standing by. Welcome to the UroGen Pharma First Quarter 2024 Earnings Call. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Vincent Perrone, Head of Investor Relations. You may begin.
Vincent Perrone
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's First Quarter 2024 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our corporate highlights and financial results for the quarter ended March 31, 2024. The press release can be accessed on the Investors portion of our website.
Joining me today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to JELMYTO, our ongoing and planned clinical trials, commercial and clinical milestones, market and revenue opportunities, our commercialization strategy and expectation, as well as potential future commercialization activities for UGN-102 if approved. Anticipated data including ENVISION durability data, regulatory filings and decisions, including UGN-102 potentially receiving priority review, UGN-102 being the primary growth driver for UroGen if approved, future R&D efforts, our corporate goals and 2024 financial guidance among other things....
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript